Creating a registry for personalized medicine in urological cancer patients using circulating tumor DNA
Official title: Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA
Run by Yonsei University · NCT04197414 · Data updated 2026-11-12
This study is trying to see if testing blood and urine for tumor DNA can help doctors better diagnose and monitor urological cancers like prostate and bladder cancer in patients who have had surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years and up |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | Yonsei University Academic / other |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | December 6, 2019 |
| Main results expected | November 2029 |
| Study ends | December 2029 |
| Registry record updated | December 13, 2019 |
| Trial ID | NCT04197414 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients diagnosed with urological malignancies who have undergone surgery at Severance Hospital and consented to participate.
✕Probably not a fit
Patients who do not have urological malignancies or those who do not agree to participate in the study will not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the usefulness of circulating tumor DNA (ctDNA) in the detection and monitoring of urological malignancies, including prostate, renal cell, bladder, and ureter cancers, within the Korean population. By analyzing ctDNA from plasma and urine samples, the study seeks to build a comprehensive database that can enhance diagnosis, track disease progression, and assess therapeutic responses. The research will focus on patients who have undergone surgeries for these cancers at Severance Hospital from December 2019 to November 2029, with the goal of developing an optimized ctDNA platform for personalized medicine.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and personalized treatment strategies for patients with urological malignancies.
How similar studies have gone: While the use of circulating tumor DNA in urological malignancies is still emerging, similar approaches in other cancer types have shown promising results, indicating potential for success in this area.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Patients diagnosed as urological malignances (prostate cancer, renal cell cancer, bladder cancer, and ureter cancer) * 2\. Patients who have undergone surgeries due to urological malignancies in Severance Hospital, Sinchon from 2019.12 and 2029.11 * 3\. Those who agree to give permission to use their human source information - 4. Those who agree with this study Exclusion Criteria: * 1\. Those who do not agree with this study * 2\. Vulnerable participants who are likely to be vulnerable to coercion or undue influence or lack decision-making
Where it's running
-
Department of Urology, Urological Science Institute, Yonsei University, Colleage of Medicine
Seoul, South Korea Recruiting
Study contacts
- Study coordinator: Won Sik Ham
- Email: uroham@yuhs.ac
- Phone: 02-2228-2310
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Creating a registry to analyze the microbiome in patients with urologic cancers
This study is trying to create a database to see how the bacteria in our bodies might affect the diagnosis and treatment of urologic cancers like prostate and bladder cancer in Korean patients.
-
A resource for collecting cancer data and biospecimens
This study is creating a resource to collect health information and samples from cancer patients and healthy individuals to help improve cancer prevention and treatment strategies.
-
Personalized 3D Tumoroids from Your Tumor to Test Treatments
Researchers are using patient tumor tissue and blood to grow personalized 3D, vascularized tumoroids with autologous immune cells to help tailor treatments for kidney, bladder, and prostate cancers.
-
Irreversible Electroporation for Recurrent Pelvic Tumors
This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.
-
AI assistant to help diagnose and treat urological diseases
A large language model-based AI tool called UroAgent will be developed and tested to help doctors diagnose and plan treatment for urinary stones, prostate cancer, and bladder cancer using past records and new patient data.
-
SL-28 for Advanced Solid Tumours
A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.